Fundz

Who to call at Elite Pharmaceuticals, Inc., and when

Fundz watches for the moments Elite Pharmaceuticals, Inc. starts buying, and tells you who to reach.

  • An alert the day Elite Pharmaceuticals, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Elite Pharmaceuticals, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Elite Pharmaceuticals, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2
Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

Elite Pharmaceuticals, Inc.

A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.

elitepharma.com
Filed: Nov 3, 2026Northvale, New JerseyCIK: 0001053369Healthcare
Full company profileView on SEC.gov

Executive Summary

Analysis of 8-K filing content

Elite Pharmaceuticals expanded its Board of Directors from four to six members by electing Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq., on October 28, 2026. Both directors bring significant pharmaceutical industry experience and will receive standard non-management director compensation.

Quick answer

Elite Pharmaceuticals, Inc. filed a Form 8-K with the SEC on November 3, 2026 under Item 5.02 (Executive Change). Elite Pharmaceuticals expanded its Board of Directors from four to six members by electing Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq., on October 28, 2026.

What did Elite Pharmaceuticals, Inc. disclose in its 8-K filed November 3, 2026?
Elite Pharmaceuticals expanded its Board of Directors from four to six members by electing Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq., on October 28, 2026. Both directors bring significant pharmaceutical industry experience and will receive standard non-management director compensation.
What does 8-K Item 5.02 (Executive Change) mean?
A senior executive or director joined, left, or changed roles. Companies generally must file it within four business days of the event.
Which other companies filed an 8-K Item 5.02 around the same time?
Enovix Corporation (November 3, 2026), ACM Research, Inc. (November 3, 2026), Wolverine World Wide, Inc. (November 3, 2026) and Accendra Health, Inc. (November 3, 2026) also filed an Item 5.02 8-K within a week of Elite Pharmaceuticals, Inc.
Where can I read the original Elite Pharmaceuticals, Inc. filing?
The original filing is on SEC EDGAR (CIK 0001053369), accession number 0001493152-26-049707.

Source: Fundz verified event record.

Other companies that filed an 8-K Item 5.02 (Executive Change) the same week

Analyzed filings with the same item number within 7 days, from SEC EDGAR via Fundz.

  • Enovix Corporation (November 3, 2026): Arthi Chakravarthy, Chief Legal Officer and Corporate Secretary of Enovix Corporation, departed from the company effective October 30, 2026.
  • ACM Research, Inc. (November 3, 2026): ACM Research appointed Yue Ma as Chief Operations Officer effective October 1, 2026, bringing semiconductor industry expertise from ASML.
  • Wolverine World Wide, Inc. (November 3, 2026): Susie Kuhn, President of Wolverine's Active Group, departed the company effective September 21, 2026.
  • Accendra Health, Inc. (November 3, 2026): Perry A. Bernocchi, Accendra Health's Executive Vice President and Chief Operating Officer, transitioned to Strategic Advisor to the CEO effective October 29, 2026, through...
  • ATN International, Inc. (November 3, 2026): ATN International extended Mary Mabey's service agreement as Senior Vice President and General Counsel through December 31, 2026, with a Transition Agreement Amendment providing...
  • VISIUM TECHNOLOGIES, INC. (November 3, 2026): Paul R. Taylor, former Chairman and CEO of Visium Technologies, resigned unconditionally on October 26, 2026, effective immediately, citing disagreements with company policies.

Key Takeaways

Board size increased from 4 to 6 directors, signaling potential strategic expansion or governance strengthening

Dr. Fatmi brings 40+ years of pharmaceutical industry experience including advisory roles at major firms like BlackRock/Tennenbaum and Strides Pharma

3 more takeaways

Filing Overview

Form Type8-K
Filing DateNov 3, 2026
Item5.02
CategoryExecutive Change
CIK0001053369
Accession #0001493152-26-049707
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
board change

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings

Elite Pharmaceuticals, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

4 screens from a live account. No signup.